SOPHiA GENETICS (SOPH) Q4 2025 earnings summary

Executive summary

• Achieved record revenue growth in 2025, with $77.3M revenue and major commercial wins, including the largest project in company history with AstraZeneca.

• Analyzed over 391,000 patients and reached 993–1,000+ global customers across 75 countries, expanding AI-driven healthcare impact.

• U.S. market remains underpenetrated but grew 50% YoY in Q4 2025, with two major health system signings expected to add 60,000 analyses annually.

• Highly recurring revenue model with annualized revenue churn below 1% and net dollar retention at 115%.

• Leadership transition: Ross Muken to become CEO in July 2026, with Jurgi Camblong moving to Executive Chairman.

Financial highlights

• FY 2025 revenue reached $77.3M, up 19% YoY; Q4 2025 revenue was $21.7M, up 22% YoY.

• Adjusted gross margin for 2025 was 74.2%, up 140 bps YoY; reported gross margin was 67.4%.

• Adjusted EBITDA loss for FY 2025 was $41.5M; adjusted operating loss was $45.5M.

• Cash and cash equivalents at year-end 2025 were $70.3M.

• Raised $15.5M via ATM facility and expanded credit facility by $25M.

Outlook and guidance

• FY 2026 revenue guidance: $92M–$94M (20–22% growth), with growth weighted to the second half.

• Adjusted EBITDA loss expected between $29M–$32M for FY 2026, improving from $41.5M in FY 2025.

• Targeting adjusted EBITDA breakeven by end of 2026 and positive in H2 2027.

• Expects continued growth in U.S. market and expansion of new applications such as Liquid Biopsy.

• Industry forecasts indicate NGS market CAGR of ~7% (2025-2026) and global genetic testing CAGR of 20%+ by 2030.